Controlling blood vessel growth in lung tumors to improve treatment outcomes
Targeting of Doppel-axis to Control Lung Tumor Angiogenesis and Immunity
This study is looking at a new way to stop tumors from growing their own blood vessels, which helps them thrive, while making sure that normal blood vessel growth in the body stays healthy, so patients with cancer might get better treatments that work well and have fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-10893956 on NIH RePORTER |
What this research studies
This research investigates how to specifically target the mechanisms that tumors use to grow their own blood vessels, a process known as angiogenesis. By focusing on the Doppel-axis, the study aims to develop new therapies that can inhibit tumor-directed angiogenesis while preserving normal physiological angiogenesis. This approach could potentially reduce the side effects associated with current anti-angiogenic treatments, which often affect healthy bodily functions. Patients may benefit from improved cancer therapies that are more effective and have fewer adverse effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older diagnosed with lung adenocarcinoma.
Not a fit: Patients with other types of cancer or those under 21 years old may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective lung cancer treatments with fewer side effects for patients.
How similar studies have performed: Previous research has shown promise in targeting angiogenesis for cancer treatment, indicating that this approach could lead to significant advancements.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Al-Hilal, Taslim a — University of Utah
- Study coordinator: Al-Hilal, Taslim a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.